The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes

Authors
Category Systematic review
Registry of Trialsclinicaltrials.gov
Year 2020
The study is a randomised double blind placebo control cross over trial with 4 weeks washout period. The expected duration of participant participation is 103 days. the study aims to investigate the effect of dapagliflozin, a SGLT2 inhibitor, on glucose flux, lipolysis and exercise in patients with type 2 diabetes.
Epistemonikos ID: 2ccdb75885125aefd675ab9043bf331534c68e1d
First added on: May 06, 2024